The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 09, 2021

Filed:

Nov. 27, 2019
Applicant:

Academia Sinica, Taipei, TW;

Inventors:

Patrick C. H. Hsieh, Tainan, TW;

Pei-Jung Wu, Taoyuan County, TW;

Steve Roffler, Taipei, TW;

Bill Cheng, Taipei, TW;

Assignee:

ACADEMIA SINICA, Taipei, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/44 (2006.01); A61K 9/00 (2006.01); A61K 47/36 (2006.01); A61K 47/42 (2017.01); A61K 47/68 (2017.01); A61K 47/60 (2017.01); A61K 9/06 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39583 (2013.01); A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/06 (2013.01); A61K 47/36 (2013.01); A61K 47/42 (2013.01); A61K 47/60 (2017.08); A61K 47/6891 (2017.08); C07K 16/44 (2013.01); A61K 38/00 (2013.01);
Abstract

Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.


Find Patent Forward Citations

Loading…